Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test

Summary by Hastings Tribune
FRIENDSWOOD, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its DecisionDx-Melanoma test has been granted Breakthrough Device designation from the U.S. Food…

2 Articles

Hastings TribuneHastings Tribune
Center

FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test

FRIENDSWOOD, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its DecisionDx-Melanoma test has been granted Breakthrough Device designation from the U.S. Food…

Read Full Article
dermatologytimes.comdermatologytimes.com

Castle Biosciences’ DecisionDx-Melanoma Test Earns FDA Breakthrough Device Designation

Castle Biosciences’ DecisionDx-Melanoma test plays a role in melanoma management with precise risk stratification, enhancing patient outcomes and reducing unnecessary surgeries.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Hastings Tribune broke the news in on Wednesday, July 23, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Friendswood icon

Friendswood

News
For You
SearchBlindspotLocal